ARCHIVES

Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

Lawrence Corey Named President Of Fred Hutchinson Cancer Research Center

August 6, 2010

DCPC Advisors Okay New Program Project Grants In Prevention

January 27, 1995

Clinical Cooperative Groups Funding To Decrease 42.5 Mil.

October 11, 1985

Insurer Declines To Cover Avastin For Breast Cancer, Institutes Review Procedure For Exceptional Cases

October 21, 2011

Two-Month Longer Survival Found With Gliadel Wafer

March 31, 2006

Clinical Trials Approved By NCI

March 26, 2004